RU2000120184A

RU2000120184A - A METHOD FOR SUPPORTING THE GROWTH OF TUMOR CELLS MEDIATED BY RAIN KINASE, HETEROCYCLIC URECON DERIVATIVES (OPTIONS), PHARMACEUTICAL COMPOSITION (OPTIONS)

Info

Publication number: RU2000120184A
Application number: RU2000120184/14A
Authority: RU
Inventors: Джил Э ВУД; Джефри ДЖОНСОН; Жак Дюма; Юдэй КАЙРЕ; Уэнди ЛИ; Тимоти Бруно ЛОУИНГЕР; Хольгер Паульсен; Анико РЕДМЭН; Джоуэл РЕНИК; Бернд Ридль; Роберт СИБЛИ; Уильям Дж СКОТТ; Роджер Э СМИТ; Холия ХАТОУМ-МОКДАД
Original assignee: Байер Копэрейшн
Priority date: 1997-12-22
Filing date: 1998-12-22
Publication date: 2002-10-20

Claims

1. The method of suppressing the growth of tumor cells mediated by raf kinase, including the introduction of the compounds of formula I:

where means a substituted or unsubstituted, aryl or heteroaryl fragment, up to tricyclic, including up to 30 carbon atoms and having at least one 5 - or 6-membered aromatic group containing 0-4 atoms selected from the group comprising nitrogen atoms, oxygen and sulfur, moreover, if B means a substituted group, this group has one or more substituents that are independently selected from the group including halogen up to full substitution, and X _n , where n is 0-3, and each X is independently selected from group including -CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , -C (O) R ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^5' , -NR ⁵ C (O) OR ^{5 '} , -NR ⁵ C (O) R ^5' , C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ - C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₃ heteroaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, and if X is a substituted group, then this group has one or more substituents that are independently selected from the group comprising -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^5' , -NO ₂ , -NR ⁵ C (O) R ^{5 ',} -NR ⁵ C (O) OR ^5' and ALOGIA, up to full substitution by halogen; where R ⁵ and R ^{5 'are} independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to full substitution C ₁ -C ₁₀ alkyl, halogenated up to full substitution C ₂ -C ₁₀ alkenyl, halogenated up to full substitution C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With ₆ -C ₁₄ aryl, halogenated up to full substitution With ₃ -C ₁₃ heteroaryl, where Y means-O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, NR ⁵ C (O) NR ⁵ NR ^{5 '} -, -NR ⁵ C (O) -, C (O) NR ⁵ -, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m - , -CHX ^a , -CX ₂ ^a -, S (CH ₂ ) _m - and -N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, and X ^a means halogen; and Ar means a 5-10-membered aromatic structure containing 0-4 atoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, and which can be unsubstituted or substituted by halogen up to complete substitution, and optionally substituted by the group Z _n1 , where n1 = 0-3, and each Z is independently selected from the group including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , = O, -C (O) NR ⁵ R ^{5 '} , -C ( O) NR ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ NR ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, for eschenny C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl, wherein if Z is a substituted group, this group has one or more substituents selected from the group consisting of -CN, - CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , = O, - OR ⁵ , - SR ⁵ , -NO ₂ , -NR ⁵ R ^5' , - NR ⁵ C (O) R ^{5 '} , - NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl, C ₇ -C ₂₄ alkaryl, and a means a heteroaryl residue, which is selected from the group including

where R ^{1 is} selected from the group including halogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₁ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, halogenated up to complete substitution C ₁ -C ₁₀ alkyl, halogenated up to complete substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With C ₁ -C ₁₃ heteroaryl, halogenated up to full substitution With ₆ -C ₁₄ aryl and halogenated up to full substitution With ₇ -C ₂₄ alkaryl; R ^{2 is} selected from the group consisting of H, —C (O) R ⁴ , —CO ₂ R ⁴ , —C (O) NR ³ R ^{3 ′} , C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl, and when R ² means a substituted group, this group has one or more substituents which are independently selected from the group consisting of -CN, -CO ₂ R ⁴ , -C (O) -NR ³ R ^{3 '} , -NO ₂ , -OR ⁴ , -SR ⁴ and halogen up to full substitution, where R ³ and R ^{3 'are} independently selected from the group consisting of H, -OR ⁴ , -SR ⁴ , -NR ⁴ R ^4' , -C (O) R ⁴ , -CO ₂ R ⁴ , -C (O) NR ⁴ R ^{4 ',} C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to complete substitution of C ₁ -C ₁₀ alkyl halogenated up to complete substitution of C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution of C ₆ -C ₁₄ aryl, halogenated up to full substitution of C ₃ -C ₁₃ heteroaryl; where R ⁴ and R ^{4 'are} independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to full substitution C ₁ -C ₁₀ alkyl, halogenated up to full substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution C ₆ -C ₁₄ aryl, halogenated up to full substitution With ₃ -C ₁₃ heteroaryl, R ^a means C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With ₁ -C ₁₀ alkyl, halogenated up to full replacement Yenia C ₃ -C ₁₀ cycloalkyl; and R ^b means hydrogen or halogen, R ^c means hydrogen, halogen, C ₁ -C ₁₀ alkyl, halogenated up to full substitution of C ₁ -C ₁₀ alkyl, or in combination with R ¹ and carbon atoms in the ring to which R is attached ¹ and R ^c forms a 5 or 6 membered cycloalkyl, aryl or heteroaryl ring in which 0-2 atoms are selected from the group consisting of O, N and S, with the proviso that, if A means

In is not

where n = 2-4, or

2. The method according to p. 1, characterized in that means a cyclic structure up to tricyclic aromatic structure, which is selected from the group including

which is substituted or unsubstituted with halogen up to complete substitution, and where n = 0-3, and each X is independently selected from the group including -CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , -C ( O) R ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , - NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₃ heteroaryl, C ₄ -C ₂₃ alkheteroaryl, and substituted C ₁ -C ₁₀ alkyl, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, and if X means a substituted group, then this group has one silt and more substituents that are independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NO ₂ , -NR ⁵ C (O) R ^5' , -NR ⁵ C (O) OR ^{5 '} and halogen up to full substitution; where R ⁵ and R ^{5 'are} independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to full substitution C ₁ -C ₁₀ alkyl, halogenated up to full substitution C ₂ -C ₁₀ alkenyl, halogenated up to full substitution C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With ₆ -C ₁₄ aryl, halogenated up to full substitution With ₃ -C ₁₃ heteroaryl, where Y means-O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ NR ^{5 '} -, -NR ⁵ C (O) -, -C (O) NR ⁵ -, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m -, -CHX ^a -, -CX ₂ ^a -, -S- (CH ₂ ) _m - and -N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, a X ^a means halogen; and Ar means a 5-10-membered aromatic structure containing 0-2 atoms selected from the group comprising nitrogen, oxygen and sulfur, and which can be unsubstituted or substituted with halogen up to complete substitution, and optionally substituted by the group Z _n1 , where n1 = 0-3, and each Z is independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , = O, -C (O) NR ⁵ R ^{5 '} , -C (O ) NR ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ R ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl substituted by d C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl, wherein if Z is a substituted group, it has one or more substituents selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^5' , = O, -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ -C ₂₄ alkaryl.

3. The method according to p. 1, characterized in that means

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, -SCH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -CX ₂ ^a - , -CX ^a H-, -CH ₂ O- and -OCH ₂ -, X ^a means halogen, Q means a six-membered aromatic structure containing 0-2 nitrogen atoms, substituted or unsubstituted with halogen until complete substitution; Q ¹ means a mono - or bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-4 atoms selected from the group comprising N, O and S, unsubstituted or substituted by halogen up to full substitution, X, Z, n, and n1 have the meanings indicated in paragraph 1, as = 0 or 1.

4. The method of claim 3, wherein Q is phenyl or pyridinyl, substituted or unsubstituted with halogen up to full substitution, Q ^{1 is} selected from the group including phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl unsubstituted or substituted with halogen up to complete substitution, or YQ ¹ means phthalimidinyl, unsubstituted or substituted with halogen up to complete substitution, and Z and X are independently selected from the group consisting of -R ⁶ , -OR ⁶ , and -NHR ⁷ , where R ⁶ means hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ cycloalkyl, and R ^{7 is} selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl, or C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, where R ⁶ and R ⁷ can be substituted with halogen up to complete substitution.

5. The method according to p. 1, characterized in that the administered compounds of the formula

where R ¹ , R ² and B have the meanings indicated in paragraph 1.

6. The method according to p. 5, characterized in that B has the formula

where Q means phenyl or pyridinyl, Q ¹ means pyridinyl, phenyl or benzothiazolyl, Y means -O-, -S-, -CH ₂ S-, -SCH ₂ -, -CH ₂ O-, -OCH ₂ - and -CH ₂ -, a Z means-SCH ₃ or -NH-C (O) -C _p H _{2p + 1} , where p = 1-4, n = 0, s = 1, and n1 = 0-1.

7. The method according to p. 1, characterized in that the administered compound, which is selected from the group including
N- (3-tert-butyl-5-pyrazolyl) -N '- (4-phenyloxyphenyl) urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (3-methylaminocarbonylphenyl) oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -methylphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- (4-phenyloxyphenyl) urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridinyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- {[4- (4-pyridinyl) -thiomethyl] phenyl} urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -oxyphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- {[4- (4-pyridinyl) -methyloxy] phenyl} urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (2-benzothiazolyl) oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) oxyphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) -oxyphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) -oxyphenyl] urea,
and their pharmaceutically acceptable salts.

8. The method according to p. 5, wherein R ¹ means tert-butyl.

9. The method according to p. 1, characterized in that the administered compound of the formula

where R ¹ and B have the meanings indicated in paragraph 1.

10. The method according to p. 9, characterized in that B has the formula

Q means phenyl or pyridinyl, Q ¹ means pyridinyl, phenyl or benzothiazolyl, Y means -O-, -S-, -C (O) - or -CH ₂ -, X means -CH ₃ , and Z means -NH-C (O) —C _p H _{2p + 1} , where p = 1-4, —CH ₃ , —OH, —OCH ₃ , —C ₂ H ₅ , —CN or —C (O) CH ₃ , n = 0 or 1, s = 0 or 1, and n1 = 0 or 1.

11. The method according to p. 1, characterized in that they inject a compound that is selected from the group including
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-hydroxyphenyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-hydroxyphenyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-acetylphenyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- (3-benzoylphenyl) urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- (4-phenyloxyphenyl) urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-methylaminocarbonylphenyl) thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (1,2-methylenedioxy) phenyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-pyridinyl) -oxiphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-pyridyl) thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-pyridinyl) -methylphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (4-pyridinyl) oxyphenyl] urea,
N- (5-t-butyl-3-isocoxazolyl) -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (3-methyl-4-pyridinyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (3-methyl-4-pyridinyl) -thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-methyl-4-pyridinyl) -thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (4-methyl-3-pyridinyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-methyl-4-pyridinyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (2-benzothiazolyl) -oxiphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3-chloro-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) pyridyl] thiophenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {2-methyl-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (2-carbamoyl) -pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3- [4- (2-carbamoyl) -pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) -pyridyl] thiophenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3-chloro-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea and
N- (5-tert-butyl-3-isoxazolyl) -N '- {[4- (3-methylcarbamoyl) -phenyl] oxyphenyl} urea
and their pharmaceutically acceptable salts.

12. The method according to p. 10, wherein R ¹ means tert-butyl.

13. The method according to p. 1, characterized in that the administered compound of the formula

where R ¹ and B have the meanings indicated in paragraph 1.

14. The method according to p. 13, characterized in that B has the formula

Q means phenyl or pyridinyl, Q ¹ means phenyl, benzothiazolyl or pyridinyl, Y means -O-, -S-, or -CH ₂ -, Z means -CH ₃ , -Cl, -OC ₂ H ₅ or -OCH ₃ n = 0, s = 1, and n1 = 0 or 1.

15. The method according to p. 1, characterized in that they inject a compound that is selected from the group including
N- (3-isopropyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) thiophenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-methoxyphenyl) -oxyphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {5- [2- (4-acetylphenyl) oxy] -pyridinyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) -methylphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) thiophenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-methyl-3-pyridinyl) -oxyphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [3- (2-benzothiazolyl) -oxyphenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [4- (4-methylphenyl) oxyphenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [4- (4-pyridinyl) thiophenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- {5- [2- (4-methoxyphenyl) oxy] pyridinyl} urea,
N- [3- (1-methyl-1-ethylpropyl) -5-isoxazolyl] -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- [3- (1-methyl-1-ethylpropyl) -5-isoxazolyl] -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- (3-isopropyl-5-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-isopropyl-5-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] thiophenyl} urea,
N- [3- (1,1-dimethylprop-1-yl) -5-isoxazolyl] -N '- {3- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- [3- (1,1-dimethylprop-1-yl) -5-isoxazolyl] -N '- {4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {3-chloro-4- [4- (2-methylcarbamoyl) pyridyl] thiophenyl} urea
and their pharmaceutically acceptable salts.

16. The method according to p. 13, wherein R ¹ means tert-butyl.

17. The method according to p. 1, characterized in that the administered compound of the formula

where R ¹ , R ^b and B have the meanings indicated in paragraph 1.

18. The method according to p. 17, wherein B has the formula

where Q means phenyl, Q ¹ means phenyl or pyridinyl, Y means -O- or -S-, Z means -Cl, -CH ₃ , -OH or -OCH ₃ , n = 0, s = 0 or 1, and n1 = 0-2.

19. The method according to p. 1, characterized in that the administered compound, which is selected from the group including
N- (5-tert-butyl-3-thienyl) -N '- [4- (3-methylphenyl) oxyphenyl] urea,
N- (5-tert-butyl-3-thienyl) -N '- [4- (4-hydroxyphenyl) oxyphenyl] urea,
N- (5-tert-butyl-3-thienyl) -N '- [4- (4-methoxyphenyl) oxyphenyl] urea,
N- (5-tert-butyl-3-thienyl) -N '- [4- (4-pyridinyl) thiophenyl] urea
and their pharmaceutically acceptable salts.

20. The method according to p. 17, wherein R ¹ means tert-butyl.

21. The method according to p. 1, characterized in that the administered compound of the formula

where R ^a and ^b have the meanings indicated in paragraph 1.

22. The method according to p. 21, characterized in that B has the formula

where Q means phenyl, Q ¹ means phenyl or pyridinyl, Y means -O- or -S-, s = 1, n = 0, and n1 = 0.

23. The method according to p. 2, characterized in that they inject a compound that is selected from the group including
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- [4- (4-pyridinyl) oxyphenyl] urea
and their pharmaceutically acceptable salts.

24. The method according to p. 21, wherein R ^a means CF ₃ - or tert-butyl.

25. The method according to p. 1, characterized in that the compound is administered one of the formulas

or

where R ¹ and B have the meanings indicated in paragraph 1.

26. The method according to p. 25, characterized in that B means phenyl, halogenated up to full substitution, halogenated pyridinyl up to full substitution, or has the formula

where Q means phenyl, Q ¹ means phenyl or pyridinyl, Y means -O- or -S-, Z means -Cl, -CH ₃ , -OH, or -OCH ₃ , n = 0, s = 0 or 1, and n1 = 0-2.

27. The method according to p. 25, wherein R ¹ means tert-butyl.

28. The method according to p. 1, characterized in that the administered compound of the formula

where R ¹ , R ^b and B have the meanings indicated in paragraph 1.

29. The method according to p. 28, characterized in that B has the formula

where Q is phenyl, Q ¹ is phenyl or pyridinyl, and Y is -O- or -S-, Z is -Cl or -OCH ₃ , n = 0, s = 0 or 1, and n1 = 0-2.

30. The method according to p. 28, wherein R ¹ means tert-butyl.

31. The compound of the formula

where R ^{2 is} selected from the group comprising H, —C (O) R ⁴ , —CO ₂ R ⁴ , —C (O) NR ³ R ^{3 ′} , C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl, where, if R ² means a substituted group, this group has one or more substituents that are independently selected from the group consisting of -CN, -CO ₂ R ⁴ , -C (O) -NR ³ R ^{3 '} , -NO ₂ , -OR ⁴ , -SR ⁴ and halogen up to full substitution, where R ³ and R ^{3 'are} independently selected from the group consisting of H, -OR ⁴ , -SR ⁴ , -NR ⁴ R ^4' , -C (O) R ⁴ , -CO ₂ R ⁴ , -C (O) NR ⁴ R ^{4 '} , C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to the complete substitution of C ₁ -C ₁₀ alkyl halogenated up to full substitution of C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution of C ₆ -C ₁₄ aryl, halogenated up to full substitution of C ₃ -C ₁₃ heteroaryl, where R ⁴ and R ^{4 'are} independently selected from the group, including H, C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to complete substitution WITH ₁ -C ₁₀ alkyl, halogenated up to full substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With ₆ -C ₁₄ aryl, halogenated up to full substitution With ₃ -C ₁₃ heteroaryl, where R ^{1 is} selected from the group including halogen, C ₃ -C ₁₀ alkyl, C ₁ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution of C ₁ -C ₁₀ alkyl, halogenated up to complete substitution of C ₃ -C ₁₀ cycloalkyl, halogenated up to complete substitution of C ₁ -C ₁₃ heteroaryl, halogenated up to fully substitution of C ₆ -C ₁₄ aryl and halogenated up to full substitution of C ₇ -C ₂₄ alkaryl; R ^c means hydrogen, halogen, C ₁ -C ₁₀ alkyl, halogenated up to the complete substitution of C ₁ -C ₁₀ alkyl, or in combination with R ¹ and carbon atoms in the ring, to which R ¹ and R ^{c are} attached, forms 5- or a 6-membered cycloalkyl-, aryl- or heteroaryl ring, in which 0-2 atoms are selected from the group consisting of O, N and S, B means a cyclic structure, up to a tricyclic aromatic structure, which is chosen from the group including

substituted or unsubstituted with halogen up to complete substitution, and where n = 0-2, and each X ^{1 is} independently selected from the group X or from the group including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -NO ₂ , -NR ⁵ R ^5' , C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl and C ₇ -C ₂₄ alkaryl, and X is selected from the group consisting of -SR ⁵ , -NR ⁵ C (O) OR ^{5 '} , -NR ⁵ C (O) R ^5' , C ₃ -C ₁₃ heteroaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl,
substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₆ -C ₁₄ aryl, substituted C ₇ -C ₂₄ alkaryl, substituted C ₃ -C ₁₃ heteroaryl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, where, if X is a substituted group, this group has one or more substituents, which are independently selected from the group including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^5' , -NO ₂ , -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^{5 '} and halogen up to full substitution; where R ⁵ and R ^{5 'are} independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to complete substitution of C ₁ -C ₁₀ alkyl, halogenated up to full substitution, C ₂ -C ₁₀ alkenyl, halogenated up to full substitution of C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With ₆ -C ₁₄ aryl, halogenated up to full substitution With ₃ -C ₁₃ heteroaryl, where Y means-O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ NR ^{5 '} -, -NR ⁵ C (O) -, -C (O) NR ⁵ -, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m -, -CHX ^a -, -CX ₂ ^a -, -S- (CH ₂ ) _m , - and -N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, a X ^a means halogen; and Ar means a 5-10 membered aromatic structure containing 0-2 atoms from the group including nitrogen, oxygen and sulfur atoms, unsubstituted or substituted with halogen up to full substitution, and optionally substituted with Z _n1 , where n1 = 0-3, and each Z is independently selected from the group consisting of —CN, —CO ₂ R ⁵ , —C (O) R ⁵ , ═O, —C (O) NR ⁵ R ^{5 ′} , —C (O) NR ⁵ , —NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ R ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, replacing whelp C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl; where, if Z is a substituted group, this group has one or more substituents that are independently selected from the group comprising —CN, —CO ₂ R ⁵ , —C (O) NR ⁵ R ^{5 ′} , = O, -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) R ^5' , -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ -C ₂₄ alkaryl, provided that if R ¹ is tert-butyl, a R ² means methyl, B is not

32. The compound according to claim 31, characterized in that B is

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, -SCH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -CX ₂ ^a - , -CX ^a H-, -CH ₂ O- and -OCH ₂ -, X ^a means halogen, Q means a six-membered aromatic structure containing 0-2 nitrogen atoms, substituted or unsubstituted with halogen up to full substitution, Q ¹ means mono- or a bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-4 atoms selected from the group consisting of N, O and S, substituted or unsubstituted with halogen up to complete substitution, X, Z, n and n1 have the meanings specified in 31, as = 0 or 1.

33. The compound according to claim 32, wherein Q is phenyl or pyridinyl, substituted or unsubstituted with halogen up to full substitution, Q ^{1 is} selected from the group including phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl substituted or unsubstituted with halogen up to complete substitution, or -YQ ¹ means phthalimidinyl, substituted or unsubstituted with halogen up to full substitution, and Z and X are independently selected from the group consisting of -R ⁶ , -OR ⁶ , and -NHR ⁷ , where R ⁶ is hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ tsikloal yl, and R ⁷ is selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, wherein R ⁶ and R ⁷ may be substituted by halogen, up to full substitution.

34. The compound according to claim 32, wherein Q is phenyl or pyridinyl, Q ¹ is pyridinyl, phenyl or benzothiazolyl, Y is -O-, -S-, -CH ₂ S-, -SCH ₂ -, -CH ₂ O-, -OCH ₂ - or -CH ₂ -, and Z means -SCH ₃ or -NH-C (O) -C _p H _{2p + 1} , where p = 1-4, n = 0, s = 1 , and n1 = 0-1.

35. The compound according to claim 31, characterized in that it has the formula

where R ² and B have the meanings indicated in clause 31.

36. The compound according to claim 31, characterized in that it is selected from the group including
N- (3-tert-butyl-5-pyrazolyl) -N '- (4-phenyloxyphenyl) urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (3-methylaminocarbonylphenyl) oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridinyl) -thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -methylphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- (4-phenyloxyphenyl) urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridinyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- {[4- (4-pyridinyl) -thiomethyl] phenyl} urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridinyl) -oxyphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- {[4- (4-pyridinyl) -methyloxy] phenyl} urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (2-benzothiazolyl) oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) thiophenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) oxyphenyl] urea,
N- (3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) oxyphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) -thiophenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [3- (4-pyridyl) -oxyphenyl] urea,
N- (1-methyl-3-tert-butyl-5-pyrazolyl) -N '- [4- (4-pyridyl) -oxyphenyl] urea,
and their pharmaceutically acceptable salts.

37. The compound of the formula

where R ^{1 is} selected from the group including halogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₁ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, halogenated up to complete substitution C ₁ -C ₁₀ alkyl, halogenated up to complete substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With C ₁ -C ₁₃ heteroaryl, halogenated up to full substitution With ₆ -C ₁₄ aryl and halogenated up to full substitution With ₇ -C ₂₄ alkaryl; B is a cyclic structure, up to a tricyclic aromatic structure, which is selected from the group including

substituted or unsubstituted with halogen up to complete substitution, and where n = 0-2, each X ^{1 is} independently selected from the group X or from the group including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C ( O) NR ⁵ R ^{5 '} , -OR ⁵ , -NO ₂ , -NR ⁵ R ^5' , C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl C ₆ -C ₁₄ aryl and C ₇ -C ₂₄ alkaryl, and X is selected from the group consisting of-SR ⁵ , -NR ⁵ C (O) OR ^{5 '} , -NR ⁵ C (O) R ^5' , C ₃ -C ₁₃ heteroaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl,
substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₆ -C ₁₄ aryl, substituted C ₇ -C ₂₄ alkaryl, substituted C ₃ -C ₁₃ heteroaryl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, and, if X is a substituted group, this group has one or more substituents, which are independently selected from the group including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^5' , -NO ₂ , -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^{5 'and} halogen up to full substitution where R ⁵ and R ^5' are independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, up to the fully halogenated substituted C ₁ -C ₁₀ alkyl, halogenated up to full substitution of C ₂ -C ₁₀ alkenyl, halogenated up to full substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution C ₆ -C ₁₄ aryl, halogenated up to full substitution With ₃ -C ₁₃ heteroaryl, where Y means-O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ R ^{5 '} -, -NR ⁵ C (O) -, -C (O) NR ⁵ -, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m -, -SNH ^a -, -SX ₂ ^a -, -S- (CH ₂₎ _m - and -N (R ⁵⁾ (CH ₂₎ _m -, m = 1-3, and X ^a meaning r halo; and Ar means a 5-10 membered aromatic structure containing 0-2 atoms selected from the group consisting of nitrogen, oxygen and sulfur, unsubstituted or substituted by halogen up to complete substitution, and optionally substituted by the group Z _n1 , where n1 = 0- 3, and each Z is independently selected from the group consisting of —CN, —CO ₂ R ⁵ , —C (O) R ⁵ , ═O, —C (O) NR ⁵ R ^{5 ′} , —C (O) NR ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ R ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl,
C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl, where, if Z is a substituted group, this group has one or more substituents that are independently selected from the group comprising —CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , = O, -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^5' , -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ -C ₂₄ alkaryl, provided that, if R ¹ is tert-butyl, B is not

where R ⁶ means -NNS (O) -O-tert-butyl, -O-n-pentyl, -O-n-butyl, -O-n-propyl, -C (O) NH- (CH ₃ ) ₂ , —OCH ₂ CH (CH ₃ ) ₂ , or

38. The compound according to claim 37, wherein B is

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, -SH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -CX ^a ₂ , -CX ^a H-, -CH ₂ O- and -OCH ₂ -, X ^a means halogen, Q means six-membered aromatic structure containing 0-2 nitrogen atoms, unsubstituted or substituted with halogen, up to full substitution, Q ¹ means mono- or a bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-4 atoms selected from the group including N, O and S, unsubstituted or substituted by halogen up to complete substitution, X, Z, n and n1 have the meanings specified in 37, as = 0 or 1.

39. The compound according to claim 38, wherein Q is phenyl or pyridinyl, unsubstituted or substituted by halogen up to full substitution, Q ^{1 is} selected from the group comprising phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, unsubstituted or substituted with halogen up to complete substitution, or -YQ ¹ means phthalimidinyl substituted or unsubstituted with halogen up to full substitution, and Z and X are independently selected from the group consisting of -R ⁶ , -OR ⁶ and -NHR ⁷ , where R ⁶ is hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ cycloalk l, and R ⁷ is selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, wherein R ⁶ and R ⁷ may be substituted by halogen, up to full substitution.

40. The compound according to claim 38, wherein Q is phenyl or pyridinyl, Q ¹ is pyridinyl, phenyl or benzothiazolyl, Y is -O-, -S-, -C (O) - or -CH ₂ -, a Z means -NH-C (O) -C _p H _{2p + 1} , where p = 1-4, -CH ₃ , -OH, -OCH ₃ , -OC ₂ H ₅ , -CN or -C (O) CH ₃ , n = 0 or 1, s = 0 or 1, a n1 = 0 or 1.

41. The compound according to claim 37, characterized in that it is selected from the group including
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-hydroxyphenyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-hydroxyphenyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-acetylphenyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- (3-benzoylphenyl) urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- (4-phenyloxyphenyl) urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-methylamino-carbonylphenyl) thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (1,2-methylenedioxy) phenyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-pyridinyl) -oxiphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-pyridyl) thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (4-pyridinyl) -methylphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (4-pyridinyl) oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (3-methyl-4-pyridinyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (3-methyl-4-pyridinyl) -thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-methyl-4-pyridinyl) -thiophenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (4-methyl-3-pyridinyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [4- (3-methyl-4-pyridinyl) -oxyphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- [3- (2-benzothiazolyl) -oxiphenyl] urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3-chloro-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) pyridyl] thiophenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {2-methyl-4- [4- (2-methyl-carbamoyl) pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (2-carbamoyl) -pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3- [4- (2-carbamoyl) -pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) -pyridyl] thiophenyl} urea,
N- (5-tert-butyl-3-isoxazolyl) -N '- {3-chloro-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea and
N- (5-tert-butyl-3-isoxazolyl) -N '- {[4- (3-methylcarbamoyl) -phenyl] oxyphenyl} urea
and their pharmaceutically acceptable salts.

42. The compound according to claim 37, characterized in that it has the formula

where B has the meanings indicated in clause 37.

43. The compound of the formula

where R ^{1 is} selected from the group including halogen, C ₃ -C ₁₀ alkyl, C ₁ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₀ cycloalkyl, halogenated up to complete substitution C ₁ -C ₁₀ alkyl, halogenated up to complete substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With C ₁ -C ₁₃ heteroaryl, halogenated up to full substitution With ₆ -C ₁₄ aryl and halogenated up to full substitution With ₇ -C ₂₄ alkaryl and B is an aromatic cyclic structure, which is selected from the group including

substituted or unsubstituted with halogen up to complete substitution, and where n = 0-2, each X ^{1 is} independently selected from the group X or from the group including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C ( O) NR ⁵ R ^{5 '} , -OR ⁵ , -NO ₂ , -NR ⁵ R ^5' , C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl C ₆ -C ₁₄ aryl and C ₇ -C ₂₄ alkaryl, and X is selected from the group consisting of-SR ⁵ , -NR ⁵ C (O) OR ^{5 '} , -NR ⁵ C (O) R ^5' , C ₃ -C ₁₃ heteroaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl,
substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₆ -C ₁₄ aryl, substituted C ₇ -C ₂₄ alkaryl, substituted C ₃ -C ₁₃ heteroaryl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, and if X is a substituted group, then this group has one or more substituents that are independently selected from the group including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^3' , -NO ₂ , -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^{5 '} and halogen up to complete substitution, where R ⁵ and R ^{5' are} independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to fully substituted C ₁ -C ₁₀ alkyl, halogenated up to full substitution of C ₂ -C ₁₀ alkenyl, halogenated up to to full substitution of C ₃ -C ₁₀ cycloalkyl, halogenated up to complete substitution of C ₆ -C ₁₄ aryl, halogenated, up to full substitution of C ₃ -C ₁₃ heteroaryl, wherein Y is -O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ R ^{5 '} -, -NR ⁵ C (O) -, -C (O) NR ⁵ -, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m -, -CHX ^a -, -СX ₂ ^a -, -S- (CH ₂ ) _m - and -N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, and X ^a means gal ogen; and Ar means a 5-6-membered aromatic structure containing 0-2 atoms selected from the group consisting of nitrogen, oxygen and sulfur, substituted or unsubstituted by halogen up to complete substitution, and optionally substituted by the group Z _n1 , where n1 = 0- 3 and each Z is independently selected from the group consisting of —CN, —CO ₂ R ⁵ , —C (O) R ⁵ , ═O, —C (O) NR ⁵ R ^{5 ′} , —C (O) NR ⁵ , - NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ R ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl,
C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl, where, if Z is a substituted group, this group has one or more substituents that are independently selected from the group comprising —CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , = O, -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^5' , -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ -C ₂₄ alkaryl, and where R ¹ is em tert-butyl, does not mean

and, where R ¹ is —CH ₂ -t-butyl, B does not mean

44. The compound according to claim 43, wherein B means

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, -SCH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -CX ₂ ^a - , -CX ^a H-, -CH ₂ O- and -OCH ₂ -, X ^a means halogen, Q means six-membered aromatic structure containing 0-4 nitrogen atoms, substituted or unsubstituted with halogen up to full substitution, Q ¹ means mono- or a bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-2 atoms selected from the group including N, O and S, unsubstituted or substituted by halogen up to complete substitution, X, Z, n and n1 have the meanings specified in 43, as = 0 or 1.

45. The compound according to claim 44, wherein Q is phenyl or pyridinyl, substituted or unsubstituted with halogen up to full substitution, Q ^{1 is} selected from the group comprising phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted with halogen up to complete substitution, or -YQ ¹ means phthalimidinyl, substituted or unsubstituted with halogen up to full substitution, and Z and X are independently selected from the group consisting of -R ⁶ , -OR ⁶ and -NHR ⁷ , where R ⁶ means hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ cyclo-alk sludge, and R ^{7 is} selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl, or C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, and R ⁶ and R ⁷ can be substituted with halogen up to complete substitution.

46. The compound according to claim 43, characterized in that it has the formula

where B has the meanings indicated in clause 43.

47. The compound of claim 44, wherein Q is phenyl or pyridinyl, Q ¹ is phenyl, benzothiazolyl or pyridinyl, Y is -O-, -S-, or -CH ₂ -, Z is -CH ₃ , - Cl, —OC ₂ H ₅ or —OCH ₃ , n = 0, s = 1, and n1 = 0 or 1.

48. The compound according to claim 43, characterized in that it is selected from the group including
N- (3-isopropyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) thiophenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-methoxyphenyl) -oxyphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {5- [2- (4-acetylphenyl) oxy] pyridinyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [3- (4-pyridinyl) -thiophenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) -methylphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) thiophenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [4- (4-methyl-3-pyridinyl) -oxyphenyl] urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- [3- (2-benzothiazolyl) -oxyphenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [4- (4-methylphenyl) oxyphenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- [4- (4-pyridinyl) thiophenyl] urea,
N- [3- (1,1-dimethylpropyl) -5-isoxazolyl] -N '- {5- [2- (4-methoxyphenyl) oxy] pyridinyl} urea,
N- [3- (1-methyl-1-ethylpropyl) -5-isoxazolyl] -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- [3- (1-methyl-1-ethylpropyl) -5-isoxazolyl] -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- (3-isopropyl-5-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-isopropyl-5-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {4- [4- (2-methylcarbamoyl) -pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {3- [4- (2-methylcarbamoyl) -pyridyl] thiophenyl} urea,
N- [3- (1,1-dimethylprop-1-yl) -5-isoxazolyl] -N '- {3- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- [3- (1,1-dimethylprop-1-yl) -5-isoxazolyl] -N '- {4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- (3-tert-butyl-5-isoxazolyl) -N '- {3-chloro-4- [4- (2-methylcarbamoyl) pyridyl] thiophenyl} urea
and their pharmaceutically acceptable salts.

49. The compound of the formula

where R ^{1 is} selected from the group including halogen, C ₃ -C ₁₀ alkyl, C ₁ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₀ cycloalkyl, halogenated up to complete substitution C ₁ -C ₁₀ alkyl, halogenated up to complete substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With C ₁ -C ₁₃ heteroaryl, halogenated up to full substitution With ₆ -C ₁₄ aryl and halogenated up to full substitution With ₇ -C ₂₄ alkaryl; R ^b means hydrogen or halogen, and In means an aromatic cyclic structure, which is selected from the group including

substituted or unsubstituted with halogen up to complete substitution, and where n = 0-2; each X ^{1 is} independently selected from the group consisting of X, or from the group comprising -CN, -OR ⁵ , -NR ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl, and X is selected from the group including -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , -C (O) R ⁵ , -NO ₂ , -SR ⁵ , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₇ - C ₂₄ alkaryl, C ₃ -C ₁₃ heteroaryl,
C ₄ -C ₂₃ alkheteroaryl, and substituted C ₁ -C ₁₀ alkyl, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₆ -C ₁₄ aryl, substituted C _7- C _24a alkaryl, substituted C ₃ -C ₁₃ heteroaryl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, where, if X is a substituted group, this group has one or more substituents that are independently selected from the group comprising -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^5' , -NO ₂ , -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^5' and halogen up to full substitution,
where R ⁵ and R ^{5 'are} independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to full substitution C ₁ -C ₁₀ alkyl, halogenated up to full substitution C ₂ -C ₁₀ alkenyl, halogenated up to full substitution C ₃ -C ₁₀ cycloalkyl, halogenated up to complete substitution of C ₆ -C ₁₄ aryl, halogenated up to full substitution of C ₃ -C ₁₃ heteroaryl, where Y means -O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m - , -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ R ^{5 '} -, -NR ⁵ C (O) -, -C (O) NR ⁵ -, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m -, -CHX ^a -, -CX ₂ ^a -, -S- (CH ₂ ) _m - and -N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, and X ^a means halogen, and Ar means a 5-10-membered aromatic structure containing 0-2 atoms selected from the group comprising nitrogen, oxygen and sulfur, unsubstituted or substituted by halogen up to full substitution, and optionally substituted by the group Z _n1 , where n = 0-3, and each Z is independently selected from the group consisting of —CN, —CO ₂ R ⁵ , —C (O) R ⁵ , ═O, —C (O) NR ⁵ R ^{5 ′} , —C (O) NR ⁵ , —NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -R ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ R ⁵ R ^{5 ',} C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ - ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl. where, if Z is a substituted group, this group has one or more substituents, which are independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , = O, -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) R ^5' , -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ -C ₂₄ alkaryl, provided that if R ¹ is tert-butyl, a R ^b means H, B does not mean

50. The compound according to claim 49, wherein B means

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, - SCH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -CX ₂ ^a - , -CX ^a H-, -CH ₂ O-, and -OCH ₂ -, X ^a means halogen, Q means six-membered aromatic structure containing 0-2 nitrogen atoms, substituted or unsubstituted with halogen up to full substitution, Q ¹ means mono- or a bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-4 atoms selected from the group including N, O and S, unsubstituted or substituted by halogen up to complete substitution, X, Z, n and n1 have the meanings specified in 49, as = 0 or 1.

51. The compound according to claim 50, wherein Q is phenyl or pyridinyl, substituted or unsubstituted with halogen up to full substitution, Q ^{1 is} selected from the group including phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted with halogen up to complete substitution, or -YQ ¹ means phthalimidinyl, substituted or unsubstituted with halogen up to full substitution, and Z and X are independently selected from the group consisting of -R ⁶ , -OR ⁶ , and -NHR ⁷ , where R ⁶ is hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ tsikloal yl, and R ⁷ is selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, wherein R ⁶ and R ⁷ may be substituted by halogen, up to full substitution.

52. The compound according to claim 49, characterized in that it has the formula

where B has the meanings indicated in clause 49.

53. The compound according to claim 50, wherein Q is phenyl, Q ¹ is phenyl or pyridinyl, Y is -O- or -S-, Z is -Cl, -CH ₃ , -OH or -OCH ₃ , n = 0, s = 0 or 1, and n1 = 0-2.

54. The compound according to claim 49, characterized in that it is selected from the group including
N- (5-tert-butyl-3-thienyl) -N '- [4- (3-methylphenyl) oxyphenyl] urea,
N- (5-tert-butyl-3-thienyl) -N '- [4- (4-hydroxyphenyl) oxyphenyl] urea,
N- (5-tert-butyl-3-thienyl) -N '- [4- (4-methoxyphenyl) oxyphenyl] urea,
N- (5-tert-butyl-3-thienyl) -N '- [4- (4-pyridinyl) thiophenyl] urea
and their pharmaceutically acceptable salts.

55. The compound of the formula

where R ^a means C ₁ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With ₁ -C ₁₀ alkyl, halogenated up to full substitution of C ₃ -C ₁₀ cycloalkyl, and B means an aromatic cyclic structure, which choose from the group including

substituted or unsubstituted with halogen up to complete substitution, and where n = 0-2, each X ^{1 is} independently selected from the group comprising X or from the group including -CN, -NO ₂ , -OR ⁵ and C ₁ -C ₁₀ alkyl , and X is selected from the group comprising —SR ⁵ , —CO ₂ R ⁵ , —C (O) R ⁵ , —C (O) NR ⁵ R ^{5 ′} , —NR ⁵ R ^{5 ′} , —NR ⁵ C (O ) OR ^{5 '} , -NR ⁵ C (O) R ^5' , C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl and C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₃ heteroaryl,
C ₄ -C ₂₃ alkheteroaryl and substituted C ₁ -C ₁₀ alkyl, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₆ -C ₁₄ aryl, substituted C ₇ -C ₂₄ alkaryl, substituted C ₃ -C ₁₃ heteroaryl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, and, if X is a substituted group, this group has one or more substituents that are independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^5' , -NO ₂ , -NR ⁵ C (O) R ^{5 ',} -NR ⁵ C (O) OR ^5' and halogen up to full substitution where R ⁵ and R ^{5 'are} independently selected from the group consisting of C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to complete substitution With ₁ -C ₁₀ alkyl, halogenated up to full substitution With ₂ -C ₁₀ alkenyl, halogenated up to full substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution C ₆ -C ₁₄ aryl, halogenated up until complete substitution of C ₃ -C ₁₃ heteroaryl, where Y means -O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m -, -C (O) -, -CH (OH) - , - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ R ^{5 '} -, -NR ⁵ C (O) -, -C (O) NR ⁵ -, - (CH ₂ ) _m S- , - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m -, -CHX ^a -, - CX ₂ ^a -, -S- (CH ₂ ) _m - and -N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, and X ³ means halogen, and Ar means 5-10-membered aromatic structure containing 0-2 atoms selected from the group consisting of nitrogen, oxygen and sulfur, substituted or unsubstituted with halogen up to complete substitution, and optionally substituted by group Z _n1 , where n1 = 0-3, and each Z is independently selected from the group, including -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , = O, -C (O) NR ⁵ R ^{5 '} , -C (O) NR ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ R ⁵ R ^5' , C ₁ -C ₁₀ alkyl,
C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl, and substituted C ₄ -C ₂₃ alkheteroaryl, where, if Z is a substituted group, this group has one or more substituents that are independently selected from the group comprising —CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , = O, -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^5' , -NR ⁵ C (O) R ^{5 '} and -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ -C ₂₄ alkaryl.

56. The compound according to claim 55, wherein B means

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, -SCH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -CX ₂ ^a - , -CX ^a H-, -CH ₂ O- and -OCH ₂ -, X ^a means halogen, Q means six-membered aromatic structure containing 0-2 nitrogen atoms, substituted or unsubstituted with halogen up to full substitution, Q ¹ means mono- or a bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-4 atoms selected from the group including N, O and S, unsubstituted or substituted by halogen up to complete substitution, X, Z, n and n1 have the meanings specified in 55, as = 0 or 1.

57. The compound according to claim 56, wherein Q is phenyl or pyridinyl, substituted or unsubstituted with halogen up to full substitution, Q ^{1 is} selected from the group including phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted with halogen up to complete substitution, or -YQ ¹ means phthalimidinyl, substituted or unsubstituted with halogen up to full substitution, and Z and X are independently selected from the group consisting of -R ⁶ , -OR ⁶ , and -NHR ⁷ , where R ⁶ is hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ tsikloal yl, and R ⁷ is selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl or C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, wherein R ⁶ and R ⁷ may be substituted by halogen, up to full substitution.

58. The compound according to claim 55, characterized in that B has the formula

where Q means phenyl, Q ¹ means phenyl or pyridinyl, Y means -O- or -S-, s = 1, n = 0 and n1 = 0.

59. The compound according to claim 55, characterized in that it has the formula

where B has the meanings indicated in clause 55.

60. The compound according to claim 55, characterized in that it is selected from the group including
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- [3- (4-pyridinyl) thiophenyl] urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- [4- (4-pyridinyl) oxyphenyl] urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- {3- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- {4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- {3-chloro-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- {2-chloro-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- [3- (4-pyridyl) thiophenyl] urea,
N- [5-tert-butyl-2- (1-thia-3,4-diazolyl)] -N '- {2-methyl-4- [4- (2-methylcarbamoyl) pyridyl] oxyphenyl} urea and
N- [5- (1,1-dimethylprop-1-yl) -2- (1-thia-3,4-diazolyl)] -N '- [4- (3-carbamoylphenyl) oxyphenyl] urea
and their pharmaceutically acceptable salts.

61. The compound of the formula

where R ^{1 is} selected from the group including halogen, C ₃ -C ₁₀ alkyl, C ₁ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₀ cycloalkyl, halogenated up to complete substitution C ₁ -C ₁₀ alkyl, halogenated up to complete substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With C ₁ -C ₁₃ heteroaryl, halogenated up to full substitution With ₆ -C ₁₄ aryl and halogenated up to full substitution With ₇ -C ₂₄ alkaryl; B is an aromatic cyclic structure that is selected from the group consisting of

substituted or unsubstituted with halogen up to complete substitution, and where n = 0-2; each X ^{1 is} independently selected from the group consisting of X, or from the group comprising -CN, -OR ⁵ , -NR ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl, and X is selected from the group including -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , -C (O) R ⁵ , = O, -NO ₂ , -SR ⁵ , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₃ heteroaryl, C ₄ -C ₂₃ alkheteroaryl and substituted C ₁ -C ₁₀ alkyl, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₆ -C ₁₄ aryl, substituted C ₇ -C ₂₄ alkaryl, substituted C ₃ -C ₁₃ heteroaryl, substituted C ₄ -C ₂₃ alkheteroaryl and -Y-Ar, where, if X is a substituted group, then this group has one or more substituents that are independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NO ₂ , -NR ⁵ C (O) R ^5' , -NR ⁵ C (O) OR ^{5 '} and halogen up to full substitution, where R ⁵ and R ^5' independently choose from the group including H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to full substitution With ₁ -C ₁₀ alkyl, halogenated up to full substitution With ₂ -C ₁₀ alkenyl, halogenated up to full substitution With ₃ -C ₁₀ C cycloalkyl, halogenated up to full substitution of C ₆ -C ₁₄ aryl, halogenated up to full substitution of C ₃ -C ₁₃ heteroaryl, where Y means -O-, -S-, -N (R ⁵ ) -, - (CH ₂ ) _m -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ R ^{5 '} -, -NR ⁵ C (O) -, - C (O) NR ⁵ -, - (CH ₂ ) _m S-, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m -, -CHX ^a -, -СX ₂ ^a -, —S— (CH ₂ ) _m - and —N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, and X ^a is halogen; and Ar means a 5-10-membered aromatic structure containing 0-2 atoms selected from the group comprising nitrogen, oxygen and sulfur, substituted or unsubstituted by halogen up to complete substitution, and optionally substituted by group Z _n1 , where n1 = 0- 3, and each Z is independently selected from the group consisting of —CN, —CO ₂ R ⁵ , —C (O) R ⁵ , ═O, —C (O) NR ⁵ R ^{5 ′} , —C (O) NR ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , -SO ₂ R ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl,
C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl, substituted C ₇ -C ₂₄ alkaryl, and substituted C ₄ -C ₂₃ alkheteroaryl; where, if Z is a substituted group, this group has one or more substituents, which are independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , = O, -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) R ^5' , -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ - ₂₄ alkaryl.

62. The compound according to claim 61, characterized in that it has the formula

where B has the meanings indicated in clause 61.

63. The compound according to claim 61, wherein B means

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, -SCH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -СX ₂ ^a - , -CX ^a H-, -CH ₂ O- and -OCH ₂ -, X ^a means halogen, Q means six-membered aromatic structure containing 0-2 nitrogen atoms, substituted or unsubstituted with halogen up to full substitution, Q ¹ means mono- or a bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-4 atoms selected from the group including N, O and S, unsubstituted or substituted by halogen up to complete substitution, X, Z, n and n1 have the meanings specified in 61, as is 0 or 1.

64. The compound according to claim 63, wherein Q is phenyl or pyridinyl, substituted or unsubstituted with halogen up to full substitution, Q ^{1 is} selected from the group comprising phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted with halogen up to complete substitution, or -YQ ¹ means phthalimidinyl, substituted or unsubstituted with halogen up to full substitution, and Z and X are independently selected from the group consisting of -R ⁶ , -OR ⁶ , and -NHR ⁷ , where R ⁶ is hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ tsikloal yl, and R ⁷ is selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, wherein R ⁶ and R ⁷ may be substituted by halogen, up to full substitution.

65. The compound according to claim 61, wherein B means phenyl that is halogenated up to complete substitution, halogenated to pyridinyl up to full substitution, or has the formula

66. The compound of the formula

where R ^{1 is} selected from the group including halogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₁₀ cycloalkyl, C ₁ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₇ -C ₂₄ alkaryl, halogenated up to complete substitution C ₁ -C ₁₀ alkyl, halogenated up to complete substitution With ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution With C ₁ -C ₁₃ heteroaryl, halogenated up to full substitution With ₆ -C ₁₄ aryl and halogenated up to full substitution With ₇ -C ₂₄ alkaryl; R ^b means hydrogen or halogen, and where In means a cyclic aromatic structure up to tricyclic aromatic structure, which is selected from the group including

substituted or unsubstituted with halogen up to complete substitution, and where n = 0-3, and each X is independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) NR ⁵ R ^{5 '} , -C (O ) R ⁵ , -NO ₂ , OR ⁵ , -SR ⁵ , NR ⁵ R ^{5 '} , - NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl,
C ₇ -C ₂₄ alkaryl, C ₃ -C ₁₃ heteroaryl, C ₄ -C ₂₃ alkheteroaryl, and substituted C ₁ -C ₁₀ alkyl, substituted C ₂ -C ₁₀ alkenyl, substituted C ₁ -C ₁₀ alkoxy, substituted C ₃ - C ₁₀ cycloalkyl, substituted C ₄ -C ₂₃ alkheteroaryl and —Y — Ar, where, if X is a substituted group, this group has one or more substituents that are independently selected from the group consisting of —CN, —CO ₂ R ⁵ , -C (O) R ⁵ , -C (O) NR ⁵ R ^{5 '} , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^5' , -NO ₂ , -NR ⁵ C (O) R ^{5 '} , - NR ⁵ C (O) OR ^{5 '} and halogen up to complete substitution, where R ⁵ and R ^{5' are} independently selected from the group consisting of H, C ₁ -C ₁₀ alkyl, C ₂ -C ₁₀ alkenyl, C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, halogenated up to full substitution C ₁ -C ₁₀ alkyl, halogenated up to full substitution C ₂ -C ₁₀ alkenyl halogenated up to full substitution of C ₃ -C ₁₀ cycloalkyl, halogenated up to full substitution of C ₆ -C ₁₄ aryl, halogenated up to full substitution of C ₃ -C ₁₃ heteroaryl, where Y means -O-, -S-, - N (R ⁵ ) -, - (CH ₂ ) _m -, -C (O) -, -CH (OH) -, - (CH ₂ ) _m O-, -NR ⁵ C (O) NR ⁵ R ^{5 '} -, -NR ⁵ C (O) -, -C (O) NR ⁵ -, - (CH ₂ ) _m S -, - (CH ₂ ) _m N (R ⁵ ) -, -O (CH ₂ ) _m - , -CHX ^a -, -CX ₂ ^a -, -S- (CH ₂ ) _m - and -N (R ⁵ ) (CH ₂ ) _m -, m = 1-3, a X ^a means halo gene, and Ar means a 5-10-membered aromatic structure containing 0-2 atoms selected from the group comprising nitrogen, oxygen and sulfur, substituted or unsubstituted by halogen up to complete substitution, and optionally substituted by group Z _n1 , where n1 = 0-3, and each Z is independently selected from the group consisting of -CN, -CO ₂ R ⁵ , -C (O) R ⁵ , = O, -C (O) NR ⁵ R ^{5 '} , -C (O) NR ⁵ , -NO ₂ , -OR ⁵ , -SR ⁵ , -NR ⁵ R ^{5 '} , -NR ⁵ C (O) OR ^5' , -NR ⁵ C (O) R ^{5 '} , -SO ₂ R ⁵ , - SO ₂ R ⁵ R ^{5 '} , C ₁ -C ₁₀ alkyl,
C ₃ -C ₁₀ cycloalkyl, C ₆ -C ₁₄ aryl, C ₃ -C ₁₃ heteroaryl, C ₇ -C ₂₄ alkaryl, C ₄ -C ₂₃ alkheteroaryl, substituted C ₁ -C ₁₀ alkyl, substituted C ₃ -C ₁₀ cycloalkyl , substituted C ₇ -C ₂₄ alkaryl and substituted C ₄ -C ₂₃ alkheteroaryl, where, if Z is a substituted group, this group has one or more substituents that are independently selected from the group comprising —CN, —CO ₂ R ⁵ , - C (O) NR ⁵ R ^{5 '} , = O, -OR ⁵ , -SR ⁵ , -NO ₂ , -NR ⁵ R ^5' , -NR ⁵ C (O) R ^{5 '} , -NR ⁵ C (O) OR ^{5 '} , C ₁ -C ₁₀ alkyl, C ₁ -C ₁₀ alkoxy, C ₃ -C ₁₀ cycloalkyl, C ₃ -C ₁₃ heteroaryl, C ₆ -C ₁₄ aryl, C ₄ -C ₂₄ alkheteroaryl and C ₇ -C ₂₄ alkaryl.

67. The compound according to claim 66, wherein B is

where Y is selected from the group comprising -O-, -S-, -CH ₂ -, -SCH ₂ -, -CH ₂ S-, -CH (OH) -, -C (O) -, -СX ₂ ^a - , -CX ^a H-, -CH ₂ O- and -OCH ₂ -, X ^a means halogen, Q means a six-membered aromatic structure containing 0-2 nitrogen atoms, substituted or unsubstituted with halogen up to full substitution, Q ¹ means mono- or a bicyclic aromatic structure containing from 3 to 10 carbon atoms and 0-4 atoms selected from the group consisting of N, O and S, substituted or unsubstituted with halogen up to complete substitution, X, Z, n and n1 have the meanings indicated in 66, as is 0 or 1.

68. The compound according to claim 67, wherein Q is phenyl or pyridinyl, substituted or unsubstituted with halogen up to full substitution, Q ^{1 is} selected from the group including phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted with halogen up to complete substitution, or -YQ ¹ means phthalimidinyl, substituted or unsubstituted with halogen up to full substitution, and Z and X are independently selected from the group comprising -R ⁶ , -OR ⁶ , and -NHR ⁷ , where R ⁶ means hydrogen, C ₁ -C ₁₀ alkyl or C ₃ -C ₁₀ cycloalk sludge, and R ^{7 is} selected from the group consisting of hydrogen, C ₃ -C ₁₀ alkyl, C ₃ -C ₆ cycloalkyl and C ₆ -C ₁₀ aryl, and R ⁶ and R ⁷ can be replaced by halogen up to complete substitution.

69. The compound according to claim 66, characterized in that it has the formula

where B has the meanings indicated in clause 66.

70. The compound according to claim 66, wherein B has the formula

where Q means phenyl, Q ¹ means phenyl or pyridinyl, Y means -O- or -S-, Z means -Cl, or -OCH ₃ , n = 0, s = 0, and n1 = 0-2.

71. A pharmaceutical composition comprising a compound according to claim 31 and a physiologically acceptable carrier.

72. A pharmaceutical composition comprising the compound of claim 37 and a physiologically acceptable carrier.

73. A pharmaceutical composition comprising the compound of Claim 43 and a physiologically acceptable carrier.

74. A pharmaceutical composition comprising the compound of claim 49 and a physiologically acceptable carrier.

75. A pharmaceutical composition comprising a compound according to claim 55 and a physiologically acceptable carrier.

76. A pharmaceutical composition comprising a compound according to claim 61 and a physiologically acceptable carrier.

77. A pharmaceutical composition comprising the compound of claim 66 and a physiologically acceptable carrier.